Today STADA Arzneimittel AG and its long-serving chairman of the management board Hartmut Retzlaff agreed on terminating their service relationship due to personal circumstances.
Hartmut Retzlaff has resigned from his office as member of the management board, which he had laid down since June 5, 2016, with effect as of August 15, 2016. Hartmut Retzlaff will be released from his duty to perform services under his board member service agreement until the agreed termination of the service agreement on December 31, 2016.
In accordance with Number 4.2.3 Deutscher Corporate Governance Kodex, the German corporate governance code, the payments agreed between STADA and Hartmut Retzlaff on the premature termination of his contract, comprising of a severance payment and the continued payment of his salary until the end of contract on 31 December 2016, do not exceed the severance pay cap of two years‘ compensation.
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.